FDA Puts “Safety First” For Post-Market Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency’s two-pronged approach to drug safety includes bolstering internal processes and equipping physicians with better tools for safe prescribing habits.
You may also be interested in...
Indication Matters: Study Shows Trial Characteristics Of Approved Drugs Vary Widely Across Diseases
FDA data requirements supporting novel drug approvals vary widely, depending on therapeutic area, with cancer drugs given greatest leniency, suggesting products may need a clinical trial “quality grade,” according to an analysis published in the Journal of the American Medical Association. Another study shows cancer treatments are most likely to get approved on the first try.
FDA Priority-Setting Includes Fewer Meetings With NDA Sponsors
Office of New Drugs Director Jenkins tells DIA that agency is making “strategic decisions” about how many sponsor meetings it can schedule.
FDA Priority-Setting Includes Fewer Meetings With NDA Sponsors
Office of New Drugs Director Jenkins tells DIA that agency is making “strategic decisions” about how many sponsor meetings it can schedule.